The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Biotech Reports Encouraging Efficacy Data in Wet AMD, Target Price Raised 66%

Research Report
  ()
These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report. read more >

Price Target Raised on Biopharma Achieving Positive Atopic Dermatitis Study Results

Research Report
  ()
Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report. read more >

3D Systems and CollPlant Biotech to Create Bioprinted Breast Reconstruction Treatment Solutions

  ()
3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments. read more >

Anavex Posts Strong Correlated Biomarker Data in Phase 2 Adult Rett Syndrome Trial

  ()
Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome. read more >

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority

  ()
Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism. read more >

Immuno-oncology Firm Advances Lead Asset in Mesothelioma

Research Report
  ()
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. read more >

Biotech Reports Positive Preclinical COVID-19 Study Results

Research Report
  ()
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. read more >

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial

  ()
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. read more >

Clearside Biomed Shares Rise 37% on Positive Data in Phase 1/2a Wet AMD Trial

  ()
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints. read more >

Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure

  ()
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. read more >

Sorrento's COVID Test Approved in Mexico

Research Report
  ()
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. read more >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios

  ()
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. read more >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Contributed Research
  ()
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. read more >

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study

  ()
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. read more >
News Update

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer

News Update
  ()
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. read more >

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program

Research Report
  ()
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. read more >

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer

  ()
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. read more >

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma

Research Report
  ()
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. read more >

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'

Research Report
  ()
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. read more >

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug

  ()
Verastem Inc. shares reached a new 52-week high price after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. read more >

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD

Research Report
  ()
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. read more >

Analyst Highlights Two Key Catalysts for Biotech

Research Report
  ()
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. read more >

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study

  ()
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." read more >

Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder

  ()
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. read more >
News Update

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial

News Update
  ()
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. read more >
Showing Results: 1 to 25 of 97 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"The majority of VIPR's La Virginia resource ounces came from El Rubi." ❭
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"FVAN has a lot more upside potential from here." ❭
– Clive Maund, CliveMaund.com
"TRCH is looking attractive here; it broke out of a base pattern." ❭
– Clive Maund, CliveMaund.com
"We are at what looks like a nice little Buy spot for OCG." ❭
– Clive Maund, CliveMaund.com
"MAG's exploration [budget] for 2021 is $6M on a 100% basis." ❭
– Peter Krauth, Gold Resource Investor